Theracryf Director Increases Shareholding
Why we think this is neutral
The RNS announcement is a standard regulatory update regarding a director's purchase of shares. There is no indication of any material financial impact to the business, and the transaction appears to be relatively small in the context of the company's market capitalization.
Key Points
- Chief Business Officer Dr Helen Kuhlman has purchased 1,500,000 Ordinary Shares
- Dr Kuhlman's notifiable interest is now 2,555,744 Ordinary Shares, representing 0.5% of the issued Ordinary Share capital
Summary
The clinical-stage drug developer has announced that its Chief Business Officer has purchased 1.5 million shares.
Theracryf plc, the clinical stage drug development company focused on oncology and neuropsychiatry, has announced that Dr Helen Kuhlman, Chief Business Officer, has purchased 1,500,000 Ordinary Shares at a price of 0.24 pence per share. This increases Dr Kuhlman's notifiable interest to 2,555,744 Ordinary Shares, representing 0.5% of the issued Ordinary Share capital of the Company.
DIRECTOR DEALINGS